
  
    
      
        Background_NNP
        Plasma_NNP membrane_NN microparticles_NNS (_( MP_NNP )_) of_IN endothelial_NN
        origin_NN have_VBP been_VBN identified_VBN in_IN normal_JJ human_JJ blood_NN [_NN 1_CD 2_CD 3_CD ]_NN
        and_CC increased_VBN counts_NNS of_IN MP_NNP carrying_VBG endothelial_NN antigens_NNS
        were_VBD documented_VBN in_IN the_DT blood_NN of_IN patients_NNS with_IN lupus_JJ
        anticoagulant_NN [_NN 1_CD ]_NN ,_, acute_JJ coronary_JJ syndrome_NN [_NN 4_CD ]_NN ,_,
        thrombotic_JJ thrombocytopenic_JJ purpura_NN [_NN 5_CD ]_NN or_CC in_IN patients_NNS
        with_IN exacerbated_VBN multiple_JJ sclerosis_NN [_NN 6_CD ]_NN ._. Similarly_RB to_TO
        blood_NN platelets_NNS ,_, endothelial_NN cells_NNS release_VBP MP_NNP which_WDT express_VBP
        phosphatidylserine_NN (_( PS_NNP )_) on_IN their_PRP$ surface_NN ._. PS-exposing_NNP MP_NNP in_IN
        blood_NN appear_VBP to_TO act_VB as_IN the_DT catalytic_JJ surface_NN for_IN assembly_NN
        of_IN the_DT prothrombinase_NN complex_JJ [_NN 7_CD ]_NN ._. Although_IN circulating_VBG
        MP_NNP of_IN various_JJ cellular_JJ origin_NN in_IN patient_NN with_IN sepsis_NN were_VBD
        reported_VBN to_TO be_VB procoagulant_NN through_IN multiple_JJ mechanisms_NNS [_NN 8_CD
        9_CD ]_NN ,_, in_IN healthy_JJ individuals_NNS they_PRP may_MD have_VB an_DT anticoagulant_NN
        function_NN by_IN promoting_VBG the_DT generation_NN of_IN low_JJ amounts_NNS of_IN
        thrombin_NN that_WDT activate_VBP protein_NN C_NNP [_NN 2_CD ]_NN ._.
        The_DT process_NN of_IN membrane_NN vesiculation_NN and_CC MP-release_NNP in_IN
        platelets_NNS has_VBZ been_VBN shown_VBN to_TO require_VB a_DT calpain-dependent_JJ
        dissociation_NN of_IN membrane_NN proteins_NNS from_IN the_DT submembrane_NN
        cytoskeleton_NN and_CC most_RBS likely_JJ involves_VBZ intracellular_NN
        signaling_VBG by_IN platelet_NN protein_NN kinases_NNS [_NN 10_CD ]_NN ._. Besides_IN
        platelets_NNS stimulated_VBN by_IN various_JJ agonists_NNS such_JJ as_IN thrombin_NN
        with_IN collagen_NN or_CC the_DT complement_VB complex_JJ C_NNP 5_CD b-_NN 9_CD [_NN 7_CD 11_CD ]_NN ,_, a_DT
        release_NN of_IN PS-containing_NNP membrane_NN MP_NNP was_VBD demonstrated_VBN in_IN
        other_JJ cell_NN types_NNS such_JJ as_IN endotoxin-stimulated_JJ monocytes_NNS [_NN
        12_CD ]_NN ,_, polymorphonuclear_NN leucocytes_NNS stimulated_VBN with_IN the_DT
        chemotactic_JJ peptide_NN FMLP_NNP [_NN 13_CD ]_NN or_CC apoptotic_JJ T-_NNP lymphocytes_NNS
        [_NN 14_CD ]_NN ._. The_DT normal_JJ restriction_NN of_IN PS_NNP to_TO the_DT inner_JJ surface_NN
        of_IN the_DT plasma_NN membrane_NN becomes_VBZ perturbed_VBD in_IN apoptotic_JJ cells_NNS
        [_NN 15_CD 16_CD ]_NN ._. When_WRB exposed_VBN ,_, PS_NNP is_VBZ a_DT determinant_NN for_IN phagocyte_NN
        recognition_NN of_IN cells_NNS to_TO be_VB cleared_VBN ._. Plasma_NNP membrane_NN
        blebbing_VBG and_CC MP-release_NNP are_VBP generally_RB accepted_VBN as_IN typical_JJ
        signs_NNS of_IN cell_NN apoptosis_NNS [_NN 17_CD ]_NN ._.
        In_IN addition_NN to_TO a_DT possible_JJ pathophysiological_JJ role_NN of_IN
        circulating_VBG MP_NNP ,_, analysis_NN of_IN MP_NNP derived_VBD from_IN endothelial_NN
        cells_NNS may_MD be_VB a_DT valuable_JJ diagnostic_JJ marker_NN of_IN vessel_NN wall_NN
        injury_NN ._. The_DT phospholipid-binding_JJ protein_NN annexin_NN V_NNP has_VBZ a_DT
        high_JJ affinity_NN for_IN PS_NNP [_NN 18_CD ]_NN and_CC is_VBZ utilized_JJ in_IN MP_NNP detection_NN
        in_IN blood_NN and_CC in_IN cell_NN supernatants_NNS [_NN 1_CD ]_NN ._. Since_IN very_RB little_JJ
        is_VBZ known_VBN about_IN the_DT mechanism_NN of_IN MP-release_NNP from_IN endothelial_NN
        cell_NN ,_, it_PRP is_VBZ difficult_JJ to_TO judge_VB the_DT type_NN and_CC extent_NN of_IN
        endothelial_NN injury_NN represented_VBN by_IN increased_VBN plasma_NN counts_NNS
        of_IN endothelial_NN MP_NNP ._. We_PRP used_VBD flow_NN cytometry_NN to_TO study_VB the_DT
        release_NN of_IN annexin_NN V-_NNP binding_JJ membrane_NN microparticles_NNS from_IN
        cultured_JJ human_JJ umbilical_JJ vein_NN endothelial_NN cell_NN (_( HUVEC_NNP )_)
        stimulated_VBN by_IN various_JJ agonists_NNS ._. We_PRP further_RBR focused_VBN our_PRP$
        study_NN on_IN MP-release_NNP from_IN HUVEC_NNP after_IN proapoptotic_JJ
        stimulation_NN with_IN the_DT topoisomerase_NN I_PRP inhibitor_NN camptothecin_NN
        (_( CPT_NNP )_) ._. Since_IN CPT_NNP analogues_NNS become_VBP one_CD of_IN the_DT most_RBS promising_JJ
        new_JJ classes_NNS of_IN antineoplastic_JJ agents_NNS introduced_VBN into_IN the_DT
        clinic_NN in_IN recent_JJ years_NNS [_NN 19_CD ]_NN ,_, activity_NN of_IN camptothecin_NN on_IN
        endothelial_NN cells_NNS may_MD be_VB of_IN great_JJ interest_NN ._.
      
      
        Results_NNS
        
          With_IN the_DT exception_NN of_IN high_JJ concentration_NN of_IN
          ionophore_NN A_DT 23187_CD ,_, rapid_JJ stimulation_NN of_IN HUVEC_NNP with_IN various_JJ
          agonists_NNS did_VBD not_RB result_VB in_IN a_DT release_NN of_IN annexin_NN V-_NNP binding_JJ
          microparticles_NNS
          Flow_NNP cytometry_NN analysis_NN of_IN HUVEC_NNP culture_NN supernatant_NN
          demonstrated_VBN that_IN a_DT 30_CD min_NN treatment_NN with_IN 10_CD μM_NN ionophore_NN
          A_DT 23187_CD caused_VBD the_DT release_NN of_IN low_JJ counts_NNS of_IN annexin_NN
          V-_NNP binding_JJ MP_NNP (_( Fig_NNP ._. 1_LS A_DT )_) ._. Similar_JJ short-time_JJ activation_NN of_IN
          HUVEC_NNP with_IN phorbol_NN myristate_NN acetate_NN (_( PMA_NNP )_) (_( 1_CD μg_NN /_NN mL_NN )_) ,_,
          human_JJ thrombin_NN receptor_NN activating_VBG peptide_NN (_( TRAP_NNP )_) 1_CD -_: 50_CD
          μmol_NN /_NN L_NNP ,_, human_JJ thrombin_NN (_( THR_NNP )_) 0_CD ._. 1_CD -_: 10_CD NIH_NNP Unit_NNP /_NN mL_NN ,_, human_JJ
          tissue_NN plasminogen_NN activator_NN (_( TPA_NNP )_) 3_CD ._. 5_CD kU_NN /_NN mL_NN or_CC human_JJ
          angiotensin_NN II_NNP (_( AGTII_NNP )_) 1_CD μmol_NN /_NN L_NNP did_VBD not_RB cause_VB any_DT
          significant_JJ increase_NN in_IN MP-release_NNP (_( Fig_NNP ._. 1_LS A_DT )_) ._. All_DT of_IN the_DT
          agonists_NNS applied_VBN induced_VBN morphological_JJ changes_NNS in_IN HUVEC_NNP
          seen_VBN by_IN phase_NN contrast_NN light_JJ microscopy_NN ,_, which_WDT confirmed_VBD
          the_DT cellular_JJ activation_NN (_( not_RB shown_VBN )_) ._.
        
        
          Proapoptotic_NNP ,_, but_CC not_RB proinflammatory_NN ,_, stimulation_NN
          induced_VBD a_DT release_NN of_IN annexin_NN V-_NNP binding_JJ microparticles_NNS
          from_IN HUVEC_NNP
          MP_NNP count_NN increased_VBN overnight_JJ in_IN the_DT media_NNS of_IN
          unstimulated_JJ cell_NN culture_NN ,_, but_CC this_DT was_VBD not_RB enhanced_VBN by_IN
          TNFα_NNP (_( 1000_CD U_NNP /_NN mL_NN )_) or_CC by_IN LPS_NNP (_( 10_CD μg_NN /_NN mL_NN )_) ._. However_RB ,_, when_WRB
          cells_NNS were_VBD activated_VBN with_IN TNFα_NNP in_IN the_DT presence_NN of_IN
          cycloheximide_NN (_( 50_CD μg_NN /_NN mL_NN )_) to_TO promote_VB apoptosis_NNS [_NN 20_CD ]_NN ,_, a_DT
          dramatic_JJ increase_NN in_IN MP_NNP count_NN was_VBD observed_VBN ,_, as_IN compared_VBN
          to_TO TNFα_NNP or_CC cycloheximide_NN treatment_NN alone_RB (_( Fig_NNP ._. 1_LS B_NNP )_) ._.
          Similarly_RB ,_, induction_NN of_IN apoptosis_NNS with_IN 5_CD μM_NN CPT_NNP ,_, a_DT
          topoisomerase_NN I_PRP inhibitor_NN [_NN 19_CD ]_NN ,_, led_VBN to_TO a_DT release_NN of_IN
          annexin_NN V-_NNP binding_JJ MP_NNP which_WDT was_VBD prevented_VBN by_IN ZVAD_NNP ._. ZVAD_NNP
          also_RB inhibited_VBD a_DT release_NN of_IN MP_NNP from_IN unstimulated_JJ cells_NNS ,_,
          which_WDT probably_RB represents_VBZ spontaneous_JJ apoptosis_NNS of_IN
          cultured_JJ HUVEC_NNP (_( Fig_NNP ._. 1_LS B_NNP )_) ._.
        
        
          MP-release_NNP did_VBD not_RB correlate_VBP with_IN the_DT level_NN of_IN cell_NN
          apoptosis_NNS in_IN HUVEC_NNP stimulated_VBN with_IN camptothecin_NN
          Phase_NN contrast_NN microscopy_NN showed_VBD that_IN HUVEC_NNP culture_NN
          treated_VBN for_IN 24_CD hrs_NNS with_IN 5_CD μM_NN CPT_NNP (_( Fig_NNP ._. 2_LS C_NNP )_) lost_VBD
          confluence_NN with_IN about_IN 30_CD -_: 40_CD %_NN cells_NNS remaining_VBG adherent_NN ._.
          The_DT level_NN of_IN apoptosis_NNS of_IN adherent_NN cells_NNS was_VBD assessed_VBN by_IN
          using_VBG TUNEL_NNP and_CC annexin_NN V-FITC_NNP /_NN propidium_NN iodide_NN assays_NNS
          (_( Fig_NNP 3_LS )_) ._. Approximately_RB one_CD third_NN of_IN the_DT remaining_VBG
          adherent_NN cells_NNS showed_VBD annexin_NN V-_NNP binding_JJ (_( Fig_NNP ._. 3_LS B_NNP )_) and_CC
          DNA-fragmentation_NNP (_( TUNEL-positivity_NNP )_) (_( Fig_NNP ._. 3_LS C_NNP )_) ._.
          Interestingly_RB ,_, a_DT ten_CD times_NNS lower_JJR concentration_NN of_IN CPT_NNP
          (_( 500_CD nM_NN )_) also_RB induced_VBN significant_JJ MP-release_NNP after_IN only_RB 4_CD
          hrs_NNS of_IN treatment_NN (_( Fig_NNP ._. 3_LS A_DT )_) and_CC after_IN 24_CD hrs_NNS ,_, 500_CD nM_NN
          camptothecin_NN induced_VBD MP-release_NNP comparable_JJ to_TO 5_CD μM_NN CPT_NNP
          treatment_NN ,_, but_CC without_IN any_DT significant_JJ increase_NN in_IN
          annexin_NN V-_NNP binding_VBG to_TO the_DT cells_NNS or_CC DNA-fragmentation_NNP (_( Fig_NNP ._.
          3_LS B_NNP ,_, 3_CD C_NNP )_) ._. The_DT cell_NN culture_NN was_VBD still_RB confluent_NN (_( Fig_NNP ._. 2_LS B_NNP )_)
          with_IN about_IN 20_CD -_: 30_CD %_NN lower_JJR cell_NN density_NN as_IN compared_VBN with_IN
          0_CD ._. 5_CD %_NN DMSO_NNP treated_VBD HUVEC_NNP (_( Fig_NNP ._. 2_LS A_DT )_) ._. This_DT result_NN indicates_VBZ
          that_IN MP-release_NNP is_VBZ not_RB related_VBN to_TO cell_NN desquamation_NN ._. To_TO
          investigate_VB whether_IN maturation_NN of_IN the_DT cell_NN culture_NN
          influences_VBZ the_DT degree_NN of_IN MP-release_NNP from_IN HUVEC_NNP in_IN
          response_NN to_TO CPT_NNP ,_, we_PRP compared_VBD MP-release_NNP from_IN subconfluent_NN
          HUVEC_NNP (_( 50_CD %_NN of_IN confluence_NN )_) at_IN 24_CD hrs_NNS in_IN culture_NN ,_, HUVEC_NNP
          reaching_VBG confluence_NN at_IN 48_CD hrs_NNS in_IN culture_NN and_CC overgrown_NN
          HUVEC_NNP at_IN 72_CD hrs_NNS in_IN culture_NN ._. Our_PRP$ results_NNS showed_VBD that_IN
          MP-release_NNP in_IN response_NN to_TO CPT_NNP declined_VBD with_IN culture_NN
          maturation_NN ._. There_EX was_VBD also_RB a_DT change_NN of_IN the_DT sensitivity_NN of_IN
          overgrown_NN HUVEC_NNP to_TO CPT_NNP treatment_NN in_IN confluent_NN 72_CD hrs_NNS old_JJ
          culture_NN resulting_VBG in_IN the_DT higher_JJR concentration_NN of_IN CPT_NNP (_( 5_CD
          μM_NN )_) releasing_VBG higher_JJR levels_NNS of_IN MP_NNP (_( Fig_NNP ._. 4_LS )_) ._. In_IN growing_VBG
          culture_NN at_IN 24_CD hrs_NNS ,_, 500_CD nM_NN CPT_NNP caused_VBD even_RB higher_JJR
          MP-release_NNP than_IN 5_CD μM_NN CPT_NNP ._. In_IN confluent_NN HUVEC_NNP 48_CD hrs_NNS old_JJ ,_,
          the_DT MP-release_NNP induced_VBN by_IN 500_CD nM_NN and_CC 5_CD μM_NN CPT_NNP was_VBD not_RB
          significantly_RB different_JJ (_( Fig_NNP ._. 4_LS )_) ._.
        
        
          Endothelial_NNP antigens_NNS CD_NNP 105_CD and_CC CD_NNP 59_CD were_VBD both_DT
          expressed_VBD on_IN living_VBG cells_NNS ,_, apoptotic_JJ bodies_NNS and_CC other_JJ
          cell_NN fragments_NNS in_IN CPT_NNP treated_VBD HUVEC_NNP culture_NN but_CC CD_NNP 105_CD
          was_VBD absent_JJ on_IN 50_CD %_NN of_IN annexin_NN V-_NNP binding_JJ membrane_NN
          microparticles_NNS
          Using_VBG flow_NN cytometry_NN ,_, in_IN SSC_NNP vs_NNS ._. FSC_NNP plot_NN we_PRP gated_JJ
          homogeneous_JJ population_NN of_IN single_JJ living_NN cells_NNS (_( G_NNP 1_CD on_IN Fig_NNP ._.
          5_LS A_DT )_) ,_, which_WDT appeared_VBD negative_JJ in_IN propidium_NN iodide_NN staining_VBG
          (_( Fig_NNP ._. 5_LS B_NNP )_) ._. Living_VBG cells_NNS from_IN control_NN cultures_NNS as_RB well_RB as_IN
          from_IN cultures_NNS treated_VBN with_IN CPT_NNP were_VBD strongly_RB positive_JJ for_IN
          both_DT antigens_NNS CD_NNP 105_CD and_CC CD_NNP 59_CD (_( Fig_NNP ._. 5_LS C_NNP )_) ._. Expression_NNP of_IN
          CD_NNP 59_CD on_IN endothelial_NN cells_NNS was_VBD not_RB influenced_VBN by_IN 24_CD hrs_NNS
          incubation_NN with_IN 500_CD nM_NN or_CC 5_CD μM_NN CPT_NNP as_IN compared_VBN with_IN control_NN
          cells_NNS incubated_JJ with_IN 0_CD ._. 5_CD %_NN DMSO_NNP ._. Expression_NNP of_IN CD_NNP 105_CD was_VBD
          only_RB slightly_RB decreased_VBD on_IN CPT_NNP treated_VBD cells_NNS ._. Cell_NNP
          fragments_NNS >_NN 4_CD μm_NN in_IN size_NN as_IN compared_VBN with_IN standard_JJ
          beads_NNS were_VBD gated_JJ separately_RB (_( G_NNP 2_CD on_IN Fig_NNP ._. 5_LS A_DT )_) ._. Larger_NNP cell_NN
          fragments_NNS appeared_VBD positive_JJ in_IN propidium_NN iodide_NN staining_VBG
          (_( Fig_NNP ._. 5_LS B_NNP )_) ._. All_DT analyzed_VBN cell_NN fragments_NNS were_VBD positive_JJ for_IN
          CD_NNP 59_CD and_CC also_RB expressed_VBD CD_NNP 105_CD (_( Fig_NNP ._. 5_LS D_NNP )_) ._. Comparison_NNP of_IN
          areas_NNS under_IN the_DT different_JJ peaks_NNS on_IN the_DT histogram_NN (_( Fig_NNP ._.
          5_LS C_NNP ,_, 5_CD D_NNP )_) indicates_VBZ that_IN the_DT portion_NN of_IN cell_NN fragments_NNS
          corresponding_JJ to_TO apoptotic_JJ bodies_NNS and_CC necrotic_JJ cells_NNS was_VBD
          significantly_RB higher_JJR in_IN culture_NN treated_VBN with_IN 5_CD μM_NN CPT_NNP as_IN
          compared_VBN to_TO culture_NN treated_VBN with_IN 500_CD nM_NN CPT_NNP or_CC with_IN 0_CD ._. 5_CD %_NN
          DMSO_NNP alone_RB ._. In_IN a_DT separate_JJ protocol_NN we_PRP analyzed_VBD the_DT
          expression_NN of_IN CD_NNP 59_CD and_CC CD_NNP 105_CD on_IN membrane_NN MP_NNP ._. Comparison_NNP
          of_IN FSC_NNP values_NNS of_IN standard_JJ beads_NNS and_CC analyzed_VBD MP_NNP showed_VBD
          that_IN 95_CD %_NN of_IN annexin_NN V-_NNP binding_JJ MP_NNP released_VBD from_IN HUVEC_NNP were_VBD
          <_NN 1_CD μm_NN in_IN size_NN (_( range_NN 0_CD ._. 3_CD -_: 3_CD ._. 0_CD μm_NN )_) ._. Analyzed_NNP MP_NNP were_VBD
          free_JJ of_IN nucleic_JJ acids_NNS as_IN they_PRP were_VBD not_RB stained_JJ with_IN
          propidium_NN iodide_NN (_( not_RB shown_VBN )_) ._. Double-labeling_NNP flow_NN
          cytometry_NN assay_NN showed_VBD that_IN all_DT annexin_NN V-_NNP binding_JJ
          membrane_NN MP_NNP expressed_VBD CD_NNP 59_CD but_CC only_RB approximately_RB 50_CD %_NN of_IN
          these_DT expressed_VBN CD_NNP 105_CD (_( Fig_NNP ._. 6_CD )_) ._.
        
      
      
        Discussion_NNP
        Our_PRP$ previous_JJ study_NN demonstrated_VBN that_IN cultured_JJ HUVEC_NNP
        released_VBD annexin_NN V-_NNP binding_JJ membrane_NN MP_NNP in_IN response_NN to_TO
        proapoptotic_JJ stimulation_NN with_IN CPT_NNP [_NN 3_CD ]_NN ._. In_IN the_DT present_JJ
        study_NN ,_, we_PRP investigated_VBD whether_IN endothelial_NN cells_NNS release_VBP
        membrane_NN MP_NNP after_IN rapid_JJ stimulation_NN with_IN Ca_MD 2_CD +_NN -_: mobilizing_VBG
        agents_NNS or_CC after_IN overnight_JJ stimulation_NN with_IN proinflammatory_NN
        agents_NNS TNFα_NNP and_CC LPS_NNP ,_, or_CC only_RB after_IN induction_NN of_IN apoptosis_NNS ._.
        Our_PRP$ negative_JJ results_NNS with_IN thrombin_NN ,_, TRAP_NNP ,_, PMA_NNP ,_, TPA_NNP and_CC
        AGTII_NNP indicate_VBP that_IN rapid_JJ Ca_MD 2_CD +_NN -_: mobilization_NN ,_, despite_IN
        dramatic_JJ morphological_JJ changes_NNS of_IN the_DT cells_NNS ,_, does_VBZ not_RB
        result_VB in_IN MP-release_NNP from_IN HUVEC_NNP (_( Fig_NNP ._. 1_LS A_DT )_) ._. The_DT only_JJ report_NN
        showing_VBG MP-release_NNP after_IN rapid_JJ stimulation_NN with_IN a_DT
        physiologic_JJ agonist_NN is_VBZ the_DT study_NN by_IN Hamilton_NNP 
        et_CC al_NN ._. [_NN 21_CD ]_NN that_WDT demonstrated_VBD
        MP-release_NNP from_IN HUVEC_NNP with_IN the_DT complement_VB complex_JJ C_NNP 5_CD b-_NN 9_CD ._.
        This_DT membrane-attack_JJ complex_NN may_MD destabilize_VB cell_NN membrane_NN
        by_IN generating_VBG pores_VBZ in_IN phospholipid_NN bilayer_NN ._. We_PRP observed_VBD
        MP-release_NNP from_IN HUVEC_NNP after_IN short-time_JJ treatment_NN only_RB with_IN
        high_JJ concentrations_NNS (_( 10_CD μM_NN )_) of_IN A_DT 23187_CD ._. In_IN this_DT experiment_NN ,_,
        a_DT direct_JJ destabilizing_JJ effect_NN of_IN the_DT Ca_MD 2_CD +_NN -_: ionophore_NN A_DT 23187_CD
        on_IN cell_NN membrane_NN resulting_VBG in_IN MP_NNP formation_NN is_VBZ also_RB likely_JJ ._.
        Another_DT question_NN is_VBZ relation_NN of_IN plasma_NN membrane_NN blebbing_VBG
        and_CC MP-release_NNP ._. One_CD study_NN documented_VBN peroxide-induced_JJ
        membrane_NN blebbing_VBG after_IN a_DT short_JJ time_NN stimulation_NN of_IN
        endothelial_NN cells_NNS [_NN 22_CD ]_NN ._. Although_IN MP-release_NNP was_VBD not_RB
        investigated_VBN ,_, authors_NNS showed_VBD micrographs_NNS of_IN stimulated_VBN
        cells_NNS with_IN membrane_NN blebs_NNS of_IN about_IN 3_CD μm_NN in_IN diameter_NN ._. Size_NN
        of_IN majority_NN of_IN MP_NNP produced_VBD in_IN our_PRP$ experiments_NNS is_VBZ less_JJR than_IN
        1_CD μm_NN ._. This_DT difference_NN indicates_VBZ that_IN the_DT mechanism_NN of_IN
        MP-release_NNP may_MD be_VB different_JJ from_IN membrane_NN blebbing_VBG visually_RB
        observed_VBD on_IN cells_NNS by_IN conventional_JJ light_JJ microscopy_NN ._.
        We_PRP did_VBD not_RB find_VB any_DT significant_JJ MP-release_NNP from_IN HUVEC_NNP
        after_IN overnight_JJ stimulation_NN with_IN TNFα_NNP (_( Fig_NNP ._. 1_LS B_NNP )_) although_IN
        stimulation_NN of_IN the_DT HUVEC_NNP culture_NN was_VBD confirmed_VBN by_IN
        upregulation_NN of_IN CD_NNP 54_CD on_IN cell_NN surface_NN (_( not_RB shown_VBN )_) ._. In_IN
        comparison_NN ,_, Combes_NNP 
        et_CC al_NN ._. [_NN 1_CD ]_NN recorded_VBD a_DT four_CD fold_VB
        increase_NN in_IN MP_NNP count_NN in_IN HUVEC_NNP culture_NN stimulated_VBN overnight_JJ
        with_IN TNFα_NNP when_WRB compared_VBN to_TO control_VB cells_NNS ._. These_DT discrepant_NN
        results_NNS may_MD stem_VB from_IN differences_NNS in_IN HUVEC_NNP culture_NN
        conditions_NNS and_CC the_DT flow_NN cytometric_JJ assay_NN ._. In_IN our_PRP$ study_NN ,_, the_DT
        proapoptotic_JJ stimulation_NN was_VBD the_DT only_RB efficient_JJ way_NN to_TO
        release_VB membrane_NN MP_NNP from_IN HUVEC_NNP ._. Since_IN MP-release_NNP from_IN
        endothelial_NN cells_NNS after_IN proapoptotic_JJ stimulation_NN was_VBD not_RB
        studied_VBN before_RB ,_, we_PRP focused_VBD on_IN its_PRP$ characterization_NN ._. We_PRP used_VBD
        CPT_NNP ,_, an_DT inhibitor_NN of_IN topoisomerase_NN I_PRP ,_, that_WDT is_VBZ a_DT well_RB
        defined_VBN apoptogenic_JJ agent_NN belonging_VBG to_TO a_DT promising_JJ class_NN of_IN
        antineoplastic_JJ drugs_NNS [_NN 23_CD ]_NN ._. In_IN contrast_NN to_TO more_RBR
        physiological_JJ stimuli_NNS (_( i_NNP ._. e_SYM ,_, oxidative_JJ stress_NN )_) induction_NN of_IN
        apoptosis_NNS by_IN CPT_NNP is_VBZ less_RBR complex_JJ and_CC thus_RB is_VBZ a_DT better_JJR model_NN
        for_IN study_NN of_IN MP-release_NNP phenomenon_NN ._. Our_PRP$ results_NNS showed_VBD that_IN
        the_DT growth_NN stage_NN of_IN HUVEC_NNP culture_NN influenced_VBD MP_NNP release_NN in_IN
        response_NN to_TO CPT_NNP (_( Fig_NNP ._. 4_LS )_) ._. It_PRP is_VBZ difficult_JJ to_TO understand_VB why_WRB
        500_CD nM_NN CPT_NNP caused_VBD higher_JJR MP-release_NNP than_IN 5_CD μM_NN CPT_NNP in_IN
        subconfluent_NN HUVEC_NNP ._. This_DT difference_NN is_VBZ small_JJ and_CC may_MD be_VB
        influenced_VBN by_IN error_NN of_IN analysis_NN ._. It_PRP is_VBZ evident_JJ ,_, however_RB ,_,
        that_DT cell_NN culture_NN maturation_NN increased_VBD resistance_NN to_TO
        camptothecin_NN treatment_NN ._. This_DT may_MD be_VB related_VBN to_TO decreased_VBD
        DNA_NNP synthesis_NN in_IN mature_VBP confluent_NN HUVEC_NNP ._.
        Size_NN distribution_NN of_IN annexin_NN V-_NNP binding_JJ MP_NNP released_VBD from_IN
        HUVEC_NNP after_IN proapoptotic_JJ stimulation_NN was_VBD similar_JJ to_TO that_DT of_IN
        endothelial_NN MP_NNP found_VBD in_IN blood_NN [_NN 1_CD ]_NN ._. The_DT small_JJ size_NN and_CC
        the_DT absence_NN of_IN nucleic_JJ acids_NNS indicate_VBP that_IN the_DT analyzed_VBN MP_NNP
        are_VBP different_JJ from_IN apoptotic_JJ bodies_NNS formed_VBN in_IN the_DT terminal_NN
        stage_NN of_IN apoptosis_NNS ._. Our_PRP$ finding_NN of_IN CD_NNP 59_CD +_NN CD_NNP 105_CD +_NN and_CC
        CD_NNP 59_CD +_NN CD_NNP 105_CD -_: populations_NNS of_IN MP_NNP (_( Fig_NNP ._. 6_CD )_) suggests_VBZ that_IN HUVEC_NNP
        can_MD release_VB different_JJ types_NNS of_IN annexin_NN V-_NNP binding_JJ MP_NNP with_IN
        respect_NN to_TO their_PRP$ antigen_NN expression_NN ._. This_DT observation_NN
        cautions_VBZ against_IN the_DT use_NN of_IN a_DT single_JJ antigen_NN for_IN detection_NN
        of_IN endothelial_NN MP_NNP in_IN blood_NN ._. The_DT presence_NN of_IN CD_NNP 59_CD on_IN all_DT
        annexin_NN V-_NNP binding_JJ MP_NNP corresponds_NNS to_TO the_DT high_JJ expression_NN of_IN
        this_DT glycosylphosphatidylinositol_NN anchored_VBN glycoprotein_NN on_IN
        endothelial_NN cells_NNS ._. The_DT homodimeric_JJ transmembrane_NN
        glycoprotein_NN CD_NNP 105_CD (_( endoglin_NN )_) is_VBZ relatively_RB specific_JJ for_IN
        endothelial_NN cells_NNS and_CC is_VBZ abundant_JJ with_IN more_JJR than_IN 500_CD ,_, 000_CD
        copies_NNS per_IN cell_NN on_IN HUVEC_NNP [_NN 24_CD ]_NN ._. It_PRP is_VBZ not_RB clear_JJ ,_, however_RB ,_,
        why_WRB they_PRP are_VBP CD_NNP 59_CD -_: positive_JJ MP_NNP that_WDT express_VBP CD_NNP 105_CD and_CC some_DT
        that_WDT do_VBP not_RB (_( Fig_NNP ._. 6_CD )_) ._. Although_IN CD_NNP 105_CD was_VBD shown_VBN to_TO be_VB an_DT
        endothelial_NN cell_NN proliferation_NN marker_NN [_NN 25_CD ]_NN ,_, its_PRP$
        expression_NN was_VBD only_RB slightly_RB decreased_VBD on_IN CPT_NNP treated_VBD cells_NNS
        (_( Fig_NNP ._. 5_LS C_NNP )_) and_CC was_VBD stable_JJ on_IN overgrown_NN confluent_NN HUVEC_NNP up_IN to_TO
        96_CD hrs_NNS in_IN culture_NN (_( not_RB shown_VBN )_) ._. We_PRP also_RB found_VBD this_DT antigen_NN
        on_IN cell_NN fragments_NNS ,_, including_VBG apoptotic_JJ bodies_NNS (_( Fig_NNP ._. 5_LS D_NNP )_) ._.
        Since_IN CD_NNP 59_CD is_VBZ a_DT protein_NN with_IN an_DT important_JJ complement_VB
        regulatory_JJ function_NN ,_, and_CC CD_NNP 105_CD is_VBZ a_DT component_NN of_IN the_DT
        receptor_NN for_IN TGFβ_NNP ,_, there_EX may_MD be_VB functional_JJ and_CC /_NN or_CC
        diagnostic_JJ differences_NNS in_IN the_DT MP_NNP populations_NNS ._.
        It_PRP is_VBZ generally_RB accepted_VBN that_DT appearance_NN of_IN PS_NNP on_IN the_DT
        outside_JJ of_IN the_DT plasma_NN membrane_NN is_VBZ an_DT early_JJ sign_NN of_IN
        apoptosis_NNS in_IN many_JJ cell_NN types_NNS after_IN different_JJ treatments_NNS [_NN
        26_CD ]_NN ._. Chan_NNP 
        et_CC al_NN [_NN 27_CD ]_NN showed_VBD that_DT exposure_NN of_IN
        PS_NNP on_IN the_DT cell_NN surface_NN preceded_VBN DNA_NNP strand_NN breaks_NNS in_IN
        apoptosis_NNS of_IN different_JJ cell_NN lines_NNS ._. Cell_NNP membrane_NN
        vesiculation_NN and_CC release_NN of_IN MP_NNP is_VBZ considered_VBN to_TO belong_VB to_TO
        the_DT execution_NN stage_NN of_IN apoptosis_NNS where_WRB the_DT fate_NN of_IN the_DT cell_NN
        is_VBZ sealed_VBN ._. To_TO our_PRP$ surprise_NN ,_, in_IN CPT_NNP treated_VBD HUVEC_NNP the_DT
        MP-release_NNP did_VBD not_RB correlate_VBP with_IN the_DT extent_NN cell_NN
        desquamation_NN and_CC apoptosis_NNS or_CC remaining_VBG adherent_NN cells_NNS
        characterized_VBN by_IN PS_NNP exposure_NN on_IN the_DT cell_NN membrane_NN and_CC
        DNA-fragmentation_NNP (_( TUNEL_NNP )_) (_( Fig_NNP ._. 3_LS )_) ._. In_IN contrast_NN ,_, Aupeix_NNP 
        et_CC al_NN ._. [_NN 17_CD ]_NN reported_VBD that_IN the_DT
        release_NN of_IN PS-containing_NNP MP_NNP was_VBD proportional_JJ to_TO hypodiploid_NN
        DNA_NNP in_IN THP-_NNP 1_CD and_CC U-_NNP 937_CD cells_NNS stimulated_VBN by_IN various_JJ
        apoptotic_JJ agents_NNS ._. Our_PRP$ experiments_NNS with_IN 500_CD nM_NN CPT_NNP treated_VBD
        HUVEC_NNP indicate_VBP that_DT annexin_NN V-_NNP binding_JJ MP_NNP may_MD be_VB released_VBN
        from_IN adherent_NN cells_NNS at_IN initial_JJ phase_NN of_IN apoptosis_NNS before_IN
        exposure_NN of_IN PS_NNP on_IN cell_NN surface_NN or_CC DNA_NNP fragmentation_NN ._. Cell_NNP
        desquamation_NN and_CC massive_JJ formation_NN of_IN apoptotic_JJ bodies_NNS seen_VBN
        after_IN 5_CD μM_NN CPT_NNP treatment_NN did_VBD not_RB further_JJ enhance_VB the_DT
        MP-release_NNP (_( Fig_NNP ._. 3_LS )_) thus_RB supporting_VBG the_DT hypothesis_NNS that_WDT
        annexin_NN V-_NNP binding_JJ MP-release_NNP takes_VBZ place_NN in_IN the_DT initial_JJ
        phase_NN of_IN apoptosis_NNS ._. The_DT essential_JJ step_NN in_IN plasma_NN membrane_NN
        destabilization_NN and_CC MP-release_NNP very_RB likely_JJ is_VBZ a_DT
        caspase-dependent_JJ sphingomyelin_NN hydrolysis_NNS ,_, which_WDT leads_VBZ to_TO
        the_DT production_NN of_IN ceramide_NN [_NN 28_CD 29_CD 30_CD ]_NN ._. It_PRP is_VBZ possible_JJ ,_,
        however_RB ,_, that_IN sphingomyelin_NN hydrolysis_NNS and_CC MP-release_NNP may_MD
        be_VB a_DT consequence_NN of_IN the_DT action_NN of_IN initiator_NN caspases_NNS or_CC
        other_JJ ZVAD_NNP sensitive_JJ proteases_NNS rather_RB than_IN only_RB executioner_NN
        caspases_NNS [_NN 15_CD 31_CD 32_CD ]_NN ._. Our_PRP$ study_NN was_VBD performed_VBN in_IN HUVEC_NNP
        culture_NN ,_, which_WDT may_MD have_VB particular_JJ properties_NNS in_IN respect_NN of_IN
        MP_NNP release_NN when_WRB compared_VBN with_IN endothelial_NN cells_NNS from_IN other_JJ
        organs_NNS ._. Our_PRP$ finding_VBG that_IN the_DT PS_NNP is_VBZ not_RB exposed_VBN on_IN the_DT cells_NNS
        treated_VBN with_IN low_JJ concentration_NN of_IN CPT_NNP while_IN they_PRP release_VBP
        PS-containing_NNP MP_NNP may_MD suggests_VBZ that_IN these_DT cells_NNS release_VBP MP_NNP
        to_TO remove_VB PS_NNP from_IN the_DT cell_NN surface_NN as_IN a_DT protective_JJ
        mechanism_NN that_WDT may_MD counteract_VB proapoptotic_JJ stimulation_NN in_IN
        the_DT life_NN /_NN death_NN decision_NN process_NN ._.
      
      
        Conclusions_NNP
        Our_PRP$ results_NNS demonstrate_VBP that_IN HUVEC_NNP release_NN different_JJ
        populations_NNS of_IN annexin_NN V-_NNP binding_JJ membrane_NN MP_NNP in_IN response_NN to_TO
        proapoptotic_JJ stimulation_NN ._. We_PRP showed_VBD that_IN rapid_JJ stimulation_NN
        of_IN HUVEC_NNP with_IN thrombin_NN ,_, PMA_NNP ,_, TPA_NNP or_CC AGT_NNP II_NNP or_CC overnight_JJ
        stimulation_NN with_IN TNFα_NNP or_CC LPS_NNP does_VBZ not_RB induce_VB release_NN of_IN
        annexin_NN V-_NNP binding_JJ membrane_NN MP_NNP ._. Release_NNP of_IN MP_NNP after_IN
        treatment_NN with_IN camptothecin_NN very_RB likely_JJ occurs_VBZ at_IN early_JJ
        stage_NN prior_RB to_TO a_DT "_'' point_NN of_IN no_DT return_NN "_'' in_IN apoptosis_NNS ._. This_DT
        phenomenon_NN may_MD represent_VB a_DT physiologic_JJ repair_NN process_NN
        rather_RB then_RB be_VB a_DT part_NN of_IN apoptotic_JJ cell_NN death_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Monoclonal_NNP antibodies_NNS
          Phycoerythrin_NNP (_( PE_NNP )_) conjugated_JJ IgG_NNP 2_CD a_DT isotype_NN control_NN
          (_( IgG-IC_NNP )_) was_VBD obtained_VBN from_IN Immunotech_NNP ,_, (_( Marseille_NNP ,_,
          France_NNP )_) ._. Mab_NNP to_TO human_JJ CD_NNP 59_CD (_( PE-conjugated_NNP ,_, clone_NN MEM_NNP 43_CD )_)
          was_VBD from_IN Caltag_NNP Lab_NNP ._. (_( Burlingame_NNP ,_, CA_NNP )_) ,_, Mab_NNP to_TO human_JJ CD_NNP 105_CD
          (_( PE-conjugated_NNP ,_, clone_NN N_NNP 1_CD -_: 3_CD A_DT 1_LS )_) was_VBD from_IN Ancell_NNP /_NN Alexis_NNP (_( San_NNP
          Diego_NNP ,_, CA_NNP )_) ._.
        
        
          Endothelial_NNP cell_NN culture_NN
          HUVEC_NNP were_VBD obtained_VBN from_IN Clonetics_NNP (_( San_NNP Diego_NNP ,_, CA_NNP )_) and_CC
          cultured_JJ in_IN endothelial_NN cell_NN growth_NN media_NNS EGM-_NNP 2_CD
          (_( Clonetics_NNP )_) containing_VBG 2_CD %_NN of_IN fetal_JJ bovine_JJ serum_NN and_CC
          supplements_NNS ._. Cells_NNP of_IN 2_CD ndpassage_NN were_VBD used_VBN in_IN the_DT
          experiments_NNS ._. Cells_NNP were_VBD seeded_VBN at_IN a_DT density_NN of_IN 10_CD ,_, 000_CD
          cells_NNS /_NN cm_NN 2_CD in_IN polystyrene_NN Falcon_NNP six-well_JJ plates_NNS or_CC 60_CD mm_NN
          dishes_NNS (_( Becton_NNP Dickinson_NNP Labware_NNP ,_, Franklin_NNP Lakes_NNP ,_, NJ_NNP )_) and_CC
          maintained_VBN at_IN 37_CD °_NN C_NNP under_IN an_DT atmosphere_NN of_IN 5_CD %_NN of_IN CO_NNP 
          2_CD and_CC 95_CD %_NN room_NN air_NN ._. Cells_NNP were_VBD used_VBN
          for_IN experiments_NNS at_IN 48_CD hrs_NNS in_IN culture_NN when_WRB they_PRP reached_VBD
          confluence_NN ._. For_IN apoptotic_JJ assays_NNS ,_, treated_VBN culture_NN was_VBD
          washed_VBN with_IN Hanks_NNP '_POS balanced_JJ salt_NN solution_NN (_( HBSS_NNP )_) with_IN
          0_CD ._. 35_CD %_NN bovine_JJ serum_NN albumin_NN (_( HBSS_NNP /_NN BSA_NNP )_) and_CC adherent_NN cells_NNS
          were_VBD harvested_VBN with_IN 20_CD mM_NN HEPES_NNP buffer_NN with_IN 100_CD mM_NN NaCl_NNP ,_,
          0_CD ._. 5_CD %_NN BSA_NNP and_CC 10_CD mM_NN EDTA_NNP ,_, pH_NN 7_CD ._. 4_CD ._. After_IN harvest_NN ,_, cells_NNS
          were_VBD centrifuged_JJ (_( 300_CD g_SYM /_NN 5_CD min_NN )_) ,_, washed_VBN with_IN HBSS_NNP /_NN BSA_NNP and_CC
          used_VBN for_IN analysis_NN ._.
        
        
          Phase_NN contrast_NN microscopy_NN
          HUVEC_NNP cultures_NNS in_IN 6_CD -_: well_RB plates_NNS were_VBD photographed_VBN
          using_VBG CK_NNP 40_CD Olympus_NNP culture_NN microscope_NN (_( Olympus_NNP ,_, Japan_NNP )_)
          with_IN a_DT SPOT_NNP camera_NN and_CC software_NN (_( Diagnostic_NNP Instruments_NNP ,_,
          Inc_NNP ._. ,_, MI_NNP ,_, USA_NNP )_) ._. Phase_NN contrast_NN at_IN 200_CD ×_NN magnification_NN was_VBD
          used_VBN ._. The_DT culture_NN cell_NN density_NN was_VBD estimated_VBN by_IN visual_JJ
          counting_NN of_IN cells_NNS in_IN a_DT standard_JJ area_NN on_IN the_DT
          micrographs_NNS ._.
        
        
          Overnight_NNP stimulation_NN of_IN HUVEC_NNP
          Confluent_NNP HUVEC_NNP were_VBD washed_VBN with_IN HBSS_NNP and_CC incubated_JJ
          for_IN 24_CD hrs_NNS at_IN 37_CD °_NN C_NNP with_IN various_JJ agonists_NNS in_IN the_DT medium_NN :_:
          MEDIUM_NNP only_RB ;_: DMSO_NNP 0_CD ._. 5_CD %_NN (_( vehicle_NN for_IN camptothecin_NN )_) ;_: tumor_NN
          necrosis_NNS factor-α_JJ (_( TNF_NNP )_) from_IN Alexis_NNP Biochemicals_NNP (_( San_NNP
          Diego_NNP ,_, CA_NNP )_) 100_CD or_CC 1000_CD U_NNP /_NN mL_NN ;_: cycloheximide_NN (_( CHX_NNP )_) 50_CD
          μg_NN /_NN mL_NN ;_: TNF_NNP 1000_CD U_NNP /_NN mL_NN with_IN cycloheximide_NN 50_CD μg_NN /_NN mL_NN
          (_( TNF_NNP /_NN CHX_NNP )_) ;_: lipopolysaccharide_NN (_( LPS_NNP )_) 
          E_NN ._. coli_NNS 055_CD :_: B_NNP 5_CD from_IN Calbiochem_NNP (_( San_NNP
          Diego_NNP ,_, CA_NNP )_) 10_CD μg_NN /_NN mL_NN ;_: camptothecin_NN (_( CPT_NNP )_) from_IN Sigma_NNP (_( St_NNP ._.
          Louis_NNP ,_, MO_NNP )_) 5_CD μmol_NN /_NN L_NNP or_CC 500_CD nmol_NN /_NN L_NNP ;_: CPT_NNP with_IN caspase_NN
          inhibitor_NN Z-V_NNP al-_NN Ala-_NNP Asp-fluoromethyl_NNP ketone_NN (_( ZVAD_NNP )_) from_IN
          Calbiochem_NNP (_( San_NNP Diego_NNP ,_, CA_NNP )_) 50_CD μmol_NN /_NN L_NNP or_CC ZVAD_NNP 50_CD μmol_NN /_NN L_NNP
          alone_RB ._. After_IN incubation_NN ,_, media_NNS and_CC cells_NNS were_VBD harvested_VBN
          for_IN analysis_NN ._.
          In_IN a_DT study_NN of_IN MP-release_NNP in_IN subconfluent_NN ,_, confluent_NN
          and_CC overgrown_NN HUVEC_NNP culture_NN ,_, the_DT cells_NNS at_IN 24_CD hrs_NNS (_( 50_CD %_NN of_IN
          confluence_NN )_) ,_, 48_CD hrs_NNS (_( reaching_VBG confluence_NN )_) or_CC 72_CD hrs_NNS
          (_( overgrown_NN )_) in_IN culture_NN were_VBD incubated_JJ for_IN 24_CD hrs_NNS with_IN 0_CD ._. 5_CD
          %_NN DMSO_NNP ,_, 500_CD nM_NN or_CC 5_CD μM_NN CPT_NNP in_IN medium_NN ._. After_IN incubation_NN
          supernatant_NN from_IN cell_NN culture_NN was_VBD harvested_VBN and_CC annexin_NN
          V-FITC-_NNP binding_JJ MP_NNP were_VBD counted_VBN ._.
          In_IN a_DT study_NN of_IN expression_NN of_IN CD_NNP 59_CD and_CC CD_NNP 105_CD on_IN
          endothelial_NN cells_NNS ,_, apoptotic_JJ bodies_NNS and_CC other_JJ cell_NN
          fragments_NNS ,_, the_DT confluent_NN HUVEC_NNP at_IN 48_CD hrs_NNS in_IN culture_NN were_VBD
          treated_VBN for_IN 24_CD hrs_NNS with_IN 0_CD ._. 5_CD %_NN DMSO_NNP ,_, 500_CD nM_NN or_CC 5_CD μM_NN CPT_NNP in_IN
          medium_NN ._. After_IN treatment_NN the_DT cell_NN culture_NN supernatant_NN was_VBD
          separated_JJ ,_, adherent_NN cells_NNS were_VBD harvested_VBN with_IN 20_CD mM_NN HEPES_NNP
          buffer_NN with_IN 100_CD mM_NN NaCl_NNP ,_, 0_CD ._. 5_CD %_NN BSA_NNP and_CC 10_CD mM_NN EDTA_NNP ,_, pH_NN 7_CD ._. 4_CD ,_,
          and_CC pooled_VBN with_IN culture_NN supernatant_NN ._. This_DT mixture_NN of_IN
          cells_NNS ,_, apoptotic_JJ bodies_NNS and_CC other_JJ cell_NN fragments_NNS was_VBD
          centrifuged_JJ (_( 300_CD g_SYM /_NN 5_CD min_NN )_) ,_, washed_VBN with_IN HBSS_NNP /_NN BSA_NNP ,_, labeled_VBN
          in_IN aliquots_NNS with_IN saturating_VBG concentration_NN of_IN
          PE-conjugated_NNP Mab_NNP against_IN CD_NNP 105_CD or_CC CD_NNP 59_CD ,_, washed_VBD again_RB in_IN
          HBSS_NNP /_NN BSA_NNP and_CC analyzed_VBN by_IN flow_NN cytometry_NN ._.
        
        
          Short-time_NNP stimulation_NN of_IN HUVEC_NNP
          Confluent_NNP HUVEC_NNP were_VBD washed_VBN with_IN HBSS_NNP and_CC incubated_JJ
          for_IN 30_CD min_NN at_IN 37_CD °_NN C_NNP with_IN various_JJ agonists_NNS in_IN HBSS_NNP with_IN
          0_CD ._. 35_CD %_NN BSA_NNP :_: HBSS_NNP alone_RB ;_: 0_CD ._. 5_CD %_NN dimethyl_NN sulfoxide_NN (_( DMSO_NNP )_) ;_:
          ionophore_NN A_DT 23187_CD 1_CD -_: 100_CD μmol_NN /_NN L_NNP ;_: phorbol_NN myristate_NN acetate_NN
          (_( PMA_NNP )_) 1_CD μg_NN /_NN mL_NN ;_: human_JJ thrombin_NN receptor_NN activating_VBG peptide_NN
          SFLLRNP_NNP (_( TRAP_NNP )_) 1_CD -_: 50_CD μmol_NN /_NN L_NNP ;_: human_JJ thrombin_NN (_( THR_NNP )_) US_NNP FDA_NNP
          standard_JJ lot_NN J_NNP (_( Bethesda_NNP ,_, MD_NNP )_) 0_CD ._. 1_CD -_: 10_CD NIH_NNP Unit_NNP /_NN mL_NN ;_: human_JJ
          tissue_NN plasminogen_NN activator_NN (_( TPA_NNP )_) 3_CD ._. 5_CD kU_NN /_NN mL_NN or_CC human_JJ
          angiotensin_NN II_NNP (_( AGTII_NNP )_) 1_CD μmol_NN /_NN L_NNP ._. All_DT chemicals_NNS were_VBD from_IN
          Calbiochem_NNP (_( San_NNP Diego_NNP ,_, CA_NNP )_) unless_IN otherwise_RB stated_VBN ._. After_IN
          incubation_NN ,_, cell_NN cultures_NNS were_VBD observed_VBN by_IN phase_NN contrast_NN
          microscopy_NN and_CC cell_NN supernatants_NNS were_VBD collected_VBN for_IN MP_NNP
          analysis_NN ._.
        
        
          Annexin_NNP V-_NNP labeling_VBG of_IN microparticles_NNS
          One_CD hundred_CD μL_NN of_IN medium_NN or_CC cell_NN culture_NN supernatant_NN
          were_VBD incubated_JJ with_IN 4_CD μL_NN of_IN annexin_NN V-FITC_NNP from_IN BD_NNP
          PharMingen_NNP (_( San_NNP Diego_NNP ,_, CA_NNP )_) for_IN 20_CD min_NN at_IN room_NN temperature_NN
          with_IN or_CC without_IN 50_CD mM_NN EDTA_NNP to_TO estimate_VB the_DT non-specific_JJ
          binding_JJ ._. Fifty_NNP μL_NN of_IN labeled_VBN MP_NNP were_VBD added_VBN to_TO TruCount_NNP
          tubes_NNS (_( Becton_NNP Dickinson_NNP )_) containing_VBG standard_JJ beads_NNS in_IN 450_CD
          μL_NN of_IN HBSS_NNP /_NN BSA_NNP solution_NN ._. Samples_NNP were_VBD immediately_RB
          analyzed_VBN with_IN flow_NN cytometry_NN ._.
        
        
          Immunolabeling_NNP of_IN annexin_NN V-_NNP binding_JJ
          microparticles_NNS
          Medium_NNP or_CC cell_NN supernatant_NN containing_VBG MP_NNP were_VBD
          centrifuged_JJ at_IN 2_CD ,_, 700_CD g_SYM for_IN 5_CD min_NN ,_, and_CC the_DT sediment_NN was_VBD
          discarded_VBN ._. Supernatant_NNP was_VBD further_JJ centrifuged_JJ at_IN 19_CD ,_, 800_CD
          g_SYM for_IN 5_CD min_NN at_IN 10_CD °_NN C_NNP ,_, and_CC sedimented_JJ MP_NNP were_VBD resuspended_JJ
          in_IN the_DT original_JJ volume_NN of_IN HBSS_NNP /_NN BSA_NNP ._. Aliquots_NNP of_IN 50_CD μL_NN
          were_VBD incubated_JJ for_IN 20_CD min_NN at_IN room_NN temperature_NN with_IN 2_CD μL_NN
          of_IN annexin_NN V-FITC_NNP from_IN BD_NNP Pharmingen_NNP (_( San_NNP Diego_NNP ,_, CA_NNP )_) and_CC
          saturating_VBG concentrations_NNS of_IN PE-conjugated_NNP Mab_NNP ._. After_IN
          incubation_NN and_CC washing_VBG with_IN 1_CD mL_NN HBSS_NNP /_NN BSA_NNP (_( centrifuged_JJ at_IN
          19_CD ,_, 800_CD g_SYM for_IN 5_CD min_NN at_IN 10_CD °_NN C_NNP )_) samples_NNS were_VBD diluted_VBN with_IN 450_CD
          μL_NN HBSS_NNP /_NN BSA_NNP and_CC analyzed_VBN by_IN flow_NN cytometry_NN ._.
        
        
          Flow_NNP cytometry_NN of_IN endothelial_NN cells_NNS and_CC cell_NN
          fragments_NNS
          Cell_NNP samples_NNS were_VBD analyzed_VBN by_IN a_DT FACScan_NNP flow_NN cytometer_NN
          (_( Becton_NNP Dickinson_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP )_) equipped_VBN with_IN CELLQUEST_NNP
          software_NN with_IN forward_RB scatter_NN (_( FSC_NNP )_) and_CC side_NN scatter_NN
          (_( SSC_NNP )_) in_IN linear_JJ mode_NN setting_NN ._. Samples_NNP were_VBD analyzed_VBN using_VBG
          forward_RB scatter_NN (_( FSC_NNP )_) vs_NNS ._. side_NN scatter_NN (_( SSC_NNP )_) plot_NN and_CC
          propidium_NN iodide_NN (_( PI_NNP )_) fluorescence_NN vs_NNS ._. FSC_NNP plot_NN ._. Single_NNP
          cells_NNS were_VBD gated_JJ separately_RB in_IN gate_NN G_NNP 1_CD and_CC apoptotic_JJ
          bodies_NNS and_CC other_JJ cell_NN fragment_NN in_IN gate_NN G_NNP 2_CD (_( Fig_NNP ._. 5_LS )_) ._. Count_VBP
          of_IN 10_CD ,_, 000_CD gated_JJ particles_NNS was_VBD analyzed_VBN for_IN each_DT sample_NN ._.
          Apoptotic_NNP status_NN of_IN cells_NNS was_VBD assayed_JJ using_VBG Annexin_NNP
          V-FITC_NNP Apoptosis_NNP Detection_NNP Kit_NNP for_IN annexin_NN V_NNP /_NN propidium_NN
          iodide_NN cell_NN labeling_VBG and_CC using_VBG Apo-_NNP Direct_NNP Kit_NNP for_IN
          terminal_NN deoxynucleotidyltransferase_NN dUTP-FITC_JJ nick_NN end_NN
          labeling_VBG (_( TUNEL_NNP )_) according_VBG to_TO manufacturer_NN 's_POS instruction_NN
          (_( BD_NNP Pharmingen_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP )_) ._. Percentages_NNP of_IN propidium_NN
          iodide-negative_JJ cells_NNS binding_JJ annexin_NN V_NNP and_CC
          TUNEL-positive_NNP cells_NNS were_VBD evaluated_VBN ._. In_IN a_DT study_NN of_IN the_DT
          expression_NN of_IN CD_NNP 59_CD and_CC CD_NNP 105_CD on_IN HUVEC_NNP ,_, histograms_NNS showing_VBG
          expression_NN of_IN CD_NNP 105_CD and_CC CD_NNP 59_CD on_IN cells_NNS (_( G_NNP 1_LS )_) and_CC cell_NN
          fragments_NNS (_( G_NNP 2_LS )_) are_VBP presented_VBN ._. Binding_NNP of_IN the_DT IgG_NNP 2_CD a_DT
          isotype_NN control_NN (_( IgG-IC_NNP )_) corresponded_VBD to_TO the_DT fluorescence_NN
          of_IN nonlabeled_JJ cells_NNS and_CC cell_NN fragments_NNS ._. Standard_NNP Quantum_NNP
          TM_NNP 24_CD beads_NNS (_( Flow_NNP Cytometry_NNP Standards_NNP ,_, San_NNP Juan_NNP ,_, PR_NNP )_) were_VBD
          run_VBN each_DT day_NN as_IN a_DT separate_JJ sample_NN to_TO standardize_VB
          fluorescence_NN readings_NNS ._.
        
        
          Flow_NNP cytometry_NN analysis_NN of_IN endothelial_NN cell_NN
          membrane_NN microparticles_NNS
          MP_NNP were_VBD analyzed_VBN in_IN a_DT separate_JJ protocol_NN [_NN 3_CD ]_NN using_VBG a_DT
          modified_VBN method_NN of_IN Combes_NNP et_CC al_NN ._. [_NN 1_CD ]_NN ._. Annexin_NNP
          V-FITC-_NNP positive_JJ MP_NNP were_VBD gated_JJ in_IN a_DT SSC_NNP vs_NNS ._. fluorescence_NN
          logarithmic_JJ plot_NN ._. For_IN MP_NNP quantitation_NN ,_, TruCount_NNP beads_NNS
          from_IN Becton_NNP Dickinson_NNP (_( San_NNP Diego_NNP ,_, CA_NNP )_) were_VBD used_VBN in_IN each_DT
          sample_NN as_IN an_DT internal_JJ standard_NN ._. TruCount_NNP beads_NNS were_VBD gated_JJ
          in_IN a_DT SSC_NNP vs_NNS ._. FSC_NNP logarithmic_JJ plot_NN and_CC analysis_NN was_VBD
          stopped_VBN when_WRB 5_CD ,_, 000_CD beads_NNS were_VBD counted_VBN ._. MP_NNP count_NN released_VBN
          by_IN 10_CD 3_CD cells_NNS was_VBD calculated_VBN for_IN each_DT sample_NN ._. TetraSpeck_NNP
          fluorescent_NN microsphere_NN standards_NNS of_IN 0_CD ._. 2_CD ,_, 0_CD ._. 5_CD ,_, 1_CD ._. 0_CD and_CC
          4_CD ._. 0_CD μm_NN in_IN diameter_NN from_IN Molecular_NNP Probes_NNP (_( Eugene_NNP ,_, OR_NNP )_)
          were_VBD used_VBN to_TO estimate_VB MP_NNP size_NN based_VBN on_IN comparison_NN of_IN FSC_NNP
          values_NNS ._. Antigen_NNP expression_NN on_IN MP_NNP was_VBD analyzed_VBN by_IN
          double-labeling_JJ with_IN annexin_NN V-FITC_NNP and_CC PE-conjugated_NNP
          Mabs_NNP ._. The_DT annexin_NN V-FITC-_NNP positive_JJ MP_NNP were_VBD gated_JJ ,_, and_CC
          their_PRP$ binding_JJ of_IN PE-labeled_NNP Mabs_NNP was_VBD evaluated_VBN in_IN SSC_NNP vs_NNS ._.
          PE_NNP -_: fluorescence_NN logarithmic_JJ plots_NNS ._.
        
      
      
        Abbreviations_NNP
        AGTII_NNP ,_, angiotensin_NN II_NNP ;_: BSA_NNP ,_, bovine_JJ serum_NN albumin_NN ;_: CHX_NNP ,_,
        cycloheximide_NN ;_: CPT_NNP ,_, camptothecin_NN ;_: DMSO_NNP ,_, dimethyl_NN sulfoxide_NN ;_:
        FITC_NNP ,_, fluorescein_NN isothiocyanate_NN ;_: HBSS_NNP ,_, Hanks_NNP '_POS balanced_JJ
        salt_NN solution_NN ;_: HUVEC_NNP ,_, human_JJ umbilical_JJ vein_NN endothelial_NN
        cells_NNS ;_: IC-IgG_NNP ,_, IgG_NNP isotype_NN control_NN ;_: Mab_NNP ,_, monoclonal_NN
        antibody_NN ;_: MP_NNP ,_, microparticles_NNS ;_: PE_NNP ,_, phycoerythrin_NN ;_: PI_NNP ,_,
        propidium_NN iodide_NN ;_: PMA_NNP ,_, phorbol-myristate-acetate_JJ ;_: PS_NNP ,_,
        phosphatidylserine_NN ;_: TRAP_NNP ,_, thrombin_NN receptor_NN activating_VBG
        peptide_NN (_( SFLLRNP_NNP )_) ;_: TNF_NNP ,_, tumor_NN necrosis_NNS factor_NN ;_: TPA_NNP ,_, tissue_NN
        plasminogen_NN activator_NN ;_: TUNEL_NNP ,_, terminal_NN
        deoxynucleotidyltransferase_NN dUTP_NN nick_NN end_NN labeling_VBG ;_: ZVAD_NNP ,_,
        Z-V_NNP al-_NN Ala-_NNP Asp-fluoromethyl_NNP ketone_NN ._.
      
      
        Authors_NNP '_'' contributions_NNS
        Author_NN JŠ_NNP participated_VBD in_IN the_DT design_NN of_IN the_DT study_NN and_CC
        carried_VBD out_IN tissue_NN culture_NN and_CC flow_NN cytometry_NN experiments_NNS ._.
        Author_NN KH_NNP participated_VBD in_IN flow_NN cytometry_NN experiments_NNS and_CC in_IN
        the_DT design_NN of_IN the_DT study_NN ._. Author_NN JGV_NNP participated_VBD in_IN the_DT
        design_NN of_IN the_DT study_NN and_CC in_IN its_PRP$ coordination_NN ._.
      
    
  
